The tallest steel-framed building ever tested on an earthquake simulator started moving slowly, swaying and twisting. The ...

Students and professors will research vaccines, cancer treatments and medical applications of artificial intelligence in the ...

The Department of Housing and Urban Development had previously announced its intention to sell its current headquarters, ...

Exact Sciences Corporation’s (NASDAQ:EXAS) first quarter revenue experienced 11% rise on reported and core basis exceeding the mid pint of guidance over $19 million.

Exact Sciences Corporation. (NASDAQ: EXAS) Q1 2025 Earnings Conference Call May 1, 2025 5:00 PM ET Company Participants Derek Leckow - Vice President, Investor Relations Kevin Conroy - Chairman ...

Building upon decades of research, Exact Sciences intends to harness the additive sensitivity of multiple biomarker classes to detect more cancers in earlier stages.

Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.

Building on the success of the Cologuard ® and Oncotype ® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.

Building on the success of the Cologuard ® and Oncotype ® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.

“The Exact Sciences team is off to a good start in 2025, building on the momentum we created in the fourth quarter,” said Kevin Conroy, chairman and CEO of Exact Sciences.

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on year to $713.4 million. The company expects the full ...